Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 494

Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Dr Carolina Moreno Atanasio speaks to ecancer at ASH 2018 about updates of the iLLUMINATE trial, which uses ibrutinib in combination with obinutuzumab to treat patients with chronic lymphocytic leukaemia (CLL).

She explains that the study used ibrutinib in combination with obinutuzumab vs chlorambucil in combination with obinutuzumab in patients with previously untreated CLL.

She reports that after 7 years of follow-up has shown remarkable efficacy and tolerability. 

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation